Subregion analysis of the rat femur: a sensitive indicator of changes in bone density following treatment with thyroid hormone or bisphosphonates.
Measurement of bone mineral density (BMD) by dual X-ray absorptiometry (DXA) is a precise and accurate way to assess changes in BMD due to a variety of causes. However, the degree of bone loss may vary depending on the skeletal site examined. We postulated that interventions that change bone density would have a different effect on an area rich in trabecular bone, such as the distal femur, than on other subregions of the femur. Male Sprague-Dawley rats (325-350 g) were treated with triiodothyronine (T3), a bisphosphonate (pamidronate), or placebo for 21 days and then sacrificed. Ex vivo BMD of the proximal, distal, mid and total femur were measured by DXA. We found that mean BMD of hyperthyroid rats was significantly lower than controls at all femoral subregions. However, the difference in mean BMD between hyperthyroid and control rats was greatest at the distal femur (8.6%). In rats treated with bisphosphonate, mean BMD was significantly higher than controls at the proximal, distal, and total femur. The difference in mean BMD between controls and rats treated with bisphosphonate was greatest at the distal femur (31.8%). Furthermore, pamidronate (APD)-treated rats had lower mean mid-femur BMD than controls. We conclude that changes in BMD after treatment with bisphosphonate or T3 are greatest at the distal femur subregion, and that treatment with bisphosphonate may cause a slight reduction in mid-femur BMD. Future studies examining changes in BMD in the rat femur after interventions that alter mineral metabolism should include subregion analysis.
Rosen
H N
HN
Charles A. Dana Research Institute, Beth Israel Hospital, Boston, Massachusetts.
Middlebrooks
V L
VL
Sullivan
E K
EK
Rosenblatt
M
M
Maitland
L A
LA
Moses
A C
AC
Greenspan
S L
SL
D015502:Absorptiometry, Photon; D000818:Animals; D015519:Bone Density / Q000187:drug effects* / Q000502:physiology; D004164:Diphosphonates / Q000494:pharmacology*; D005269:Femur / Q000187:drug effects / Q000378:metabolism / Q000502:physiology*; D006980:Hyperthyroidism / Q000378:metabolism / Q000503:physiopathology; D008297:Male; D008903:Minerals / Q000378:metabolism; D000077268:Pamidronate; D051381:Rats; D017207:Rats, Sprague-Dawley; D013963:Thyroid Hormones / Q000494:pharmacology*; D014284:Triiodothyronine / Q000494:pharmacology
D004164:Diphosphonates; D008903:Minerals; D013963:Thyroid Hormones; D014284:Triiodothyronine; D000077268:Pamidronate